Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of nefiracetam capsules in China. Welcome to wholesale bulk high quality nefiracetam capsules for sale here from our factory. Good service and reasonable price are available.
Nefiracetam Capsules is an oral medication for enhancing intelligence. Its contents are white crystalline powder. As a broad-spectrum pyrrolidone derivative, it has attracted much attention for its unique and powerful cognitive-enhancing effect. This drug mainly improves learning and memory abilities by efficiently regulating the glutamatergic signaling pathways in the central nervous system, especially by enhancing the current of AMPA receptors. At the same time, it can promote cholinergic nerve transmission and affect various neurotransmitter systems, thereby effectively enhancing the alertness, concentration, and information processing speed of the brain. Clinically, it is mainly used to treat age-related cognitive decline, symptoms of dementia related to Alzheimer's disease, etc., and can also counteract nerve damage caused by environmental factors such as hypoxia. Its capsule form ensures the convenience of administration and the accuracy of dosage, providing an important treatment option for patients with cognitive dysfunction.
At the same time, our company not only provides pure powders, but also tablets and injections. If needed, please feel free to contact us at any time.
Common Forms
Additional information of chemical compound:
|
|
|
Nefiracetam Powder COA
How Nefiracetam reshapes brain energy homeostasis
The brain, as the most energy intensive organ in the human body, accounts for only 2% of body weight but consumes 20% of the body's glucose. The maintenance of its energy homeostasis relies on precise regulation of glucose metabolism, glutamine cycle, lipid metabolism, and neurotransmitter system. However, neurodegenerative diseases such as Alzheimer's disease and brain damage are often accompanied by energy metabolism disorders, manifested as reduced glucose uptake, increased oxidative stress, and neurotransmitter imbalance. Nefiracetam Capsules, as a pyrrolidinone cognitive enhancer, has been shown to improve brain dysfunction by modulating neurotransmitter receptors and ion channels through multiple targets. Here is a detailed explanation:
Core pathways and homeostasis imbalance of brain energy metabolism
Glucose metabolism: the main axis of energy supply
Glucose is the main source of energy for the brain, and its metabolism is divided into three stages:
Glycolysis: Glucose is broken down into pyruvate, producing small amounts of ATP and NADH.
Tricarboxylic acid cycle (TCA): Acetoacetate is converted to acetyl CoA and enters the mitochondrial cycle to produce NADH and FADH2.
Oxidative phosphorylation: The electron transfer chain utilizes NADH/FADH2 to produce ATP while consuming oxygen.
Steady state imbalance manifestation: Alzheimer's disease patients have a 30% -50% decrease in hippocampal glucose uptake, a decrease in the activity of key glycolytic enzymes (such as hexokinase), leading to insufficient ATP synthesis.
Glutamine glutamate GABA cycle: coupling of neurotransmitters and energy
Glutamine synthesis: Astrocytes convert glutamate and ammonia into glutamine for neurons to synthesize glutamate or GABA again.
Neurotransmitter release: Glutamate (excitatory) and GABA (inhibitory) regulate neuronal activity through synaptic transmission, and their synthesis consumes a large amount of ATP.
Consequences of metabolic imbalance: After traumatic brain injury, the activity of glutamine synthetase decreases, leading to the accumulation of glutamate and causing excitotoxicity, while the decrease in GABA exacerbates neuronal overexcitation.
Lipid metabolism: membrane structure and support for signal transduction
Phospholipid metabolism: The synthesis and degradation of neuronal membrane phospholipids (such as phosphatidylcholine) affect membrane fluidity and receptor function.
Lipid peroxidation: Oxidative stress leads to peroxidation of phosphatidylethanolamine (PE) and phosphatidylinositol (PI), disrupting membrane integrity.
Clinical association: Elevated levels of free fatty acids (FFA) in cerebrospinal fluid of Alzheimer's disease patients reflect lipid metabolism disorders.
Pharmacological mechanism of Nefiracetam: multi-target regulation of metabolic network
Enhancing neurotransmitter receptor function: optimizing energy utilization efficiency
AMPA/kainate receptor regulation: Nefiracetam, as an isoform regulator, enhances receptor sensitivity to glutamate and promotes synaptic plasticity. Improve synaptic transmission efficiency and reduce energy consumption for repetitive signal transduction. In rat hippocampal slices, Nefiracetam (10 μ M) increased AMPA receptor-mediated current by 2.3 times, while reducing action potential firing frequency and saving energy. NMDA receptor activation is achieved through the protein kinase C (PKC) pathway, which reduces the blockade of NMDA receptors by magnesium ions and enhances glutamatergic signaling. Activation of NMDA receptors promotes long-term potentiation (LTP), consolidates memory formation, and avoids energy consumption from repetitive encoding of short-term memory. Nicotine acetylcholine receptor (nAChR) regulation: Nefiracetam increases the excitatory postsynaptic current (EPSC) ratio mediated by nAChR, improving cholinergic transmission. Acetylcholine is a key neurotransmitter for cognitive function, and its increased efficiency reduces glucose overconsumption caused by neuronal overactivation.
Ionic channel regulation: balancing excitability and metabolic load
The activation of L/N-type calcium channels enhances the influx of calcium ions and promotes the release of neurotrophic factors (such as BDNF) by Nefiracetam. BDNF induces mitochondrial biosynthesis, increases ATP production, while inhibiting cell apoptosis and reducing energy waste. The balance of GABAergic system can be regulated by modulating GABA receptor subtypes (such as GABA_A), and Nefiracetam inhibits overexcitation, reducing glucose metabolism rate. In the Ro 5-4864 induced seizure model, Nefiracetam capsules reduced seizure frequency by 67% and restored cerebral glucose utilization (CMRglu) to baseline levels.
Antioxidant stress and neuroprotection: maintaining metabolic homeostasis
Oxidative stress inhibition: Nefiracetam reduces the generation of reactive oxygen species (ROS) and protects mitochondrial function.
Metabolomic evidence: In the methamphetamine induced neurotoxicity model, Nefiracetam increased glutathione (GSH) levels in brain tissue by 40%, while reducing lipid peroxide (MDA) content by 35%.
Glutamine cycle repair: Nefiracetam alleviates glutamate excitotoxicity by promoting the expression of glutamine synthetase in astrocytes.
Animal experiment: After treatment with Nefiracetam (10 mg/kg/d, 7 days) in rats with traumatic brain injury, the level of glutamine in the hippocampus returned to 82% of the normal value, while the control group was only 55%.
Metabolomics study: dynamic regulation of brain metabolites by Nefiracetam
Quantitative analysis of glucose metabolites
Arterial venous metabolite differences: Through arterial venous paired sampling, it was found that Nefiracetam increased net glucose uptake in the brain by 18% (p<0.01), while reducing lactate release by 12%, indicating an improvement in glycolysis efficiency.
Key enzyme expression: Nefiracetam upregulated the mRNA expression of hexokinase (HK) and pyruvate kinase (PK) in the hippocampus, reaching 1.5 times and 1.3 times higher than the control group, respectively.
Recombination of Glutamine Glutamate GABA Cycle
Metabolic flow direction: Nefiracetam treatment reduced the release of glutamine in the brain by 22%, while increasing glutamate uptake by 19%, reflecting improved circulatory efficiency.
Enhanced GABA synthesis: The level of GABA in cerebrospinal fluid increased from 0.8 μ M before treatment to 1.2 μ M (p<0.05), which was significantly correlated with a decrease in anxiety behavior score (r=-0.72).
Reprogramming of Lipid Metabolism
Changes in phospholipid composition: Nefiracetam reduces the content of oxidized phosphatidylethanolamine (OxPE) in brain tissue by 31%, while increasing the synthesis of phosphatidylserine (PS) and improving membrane stability.
Free fatty acid regulation: The treatment group's FFA levels in the brain decreased from baseline 45 μ M to 32 μ M (p<0.01), reducing mitochondrial damage caused by lipotoxicity.
Preclinical and Clinical Research: Transformation from Mechanism to Application
Energy homeostasis recovery in animal models
Repair of traumatic brain injury: In a controlled cortical injury (CCI) rat model, treatment with Nefiracetam (10 mg/kg) for 7 days resulted in a 43% reduction in escape latency in the Morris water maze test, while brain microdialysis showed a recovery of glucose levels to 90% before injury.
Alzheimer's disease intervention: After treatment with Nefiracetam (5 mg/kg/d, 3 months), APP/PS1 transgenic mice showed a 28% increase in hippocampal ATP content and a 35% decrease in amyloid plaque area.
Human pharmacokinetics and safety
Absorption and distribution: After oral administration of Nefiracetam Capsules to healthy volunteers, the time to peak blood drug concentration (Tmax) is 1.5-2.5 hours, the bioavailability is about 65%, and it can penetrate the blood-brain barrier, with cerebrospinal fluid concentration reaching 12% of blood drug concentration.
Metabolic excretion: 80% of the drug is excreted in its original form or metabolite form through urine, with a half-life (T1/2) of 4-6 hours, supporting a 2-3 time daily dosing regimen.
Safety: Phase I/II clinical trials have shown that Nefiracetam has no serious adverse reactions at doses ≤ 600 mg/d, with common side effects being mild dry mouth (12%) and insomnia (8%).
Challenges and Future Directions
Heterogeneity of Individualized Metabolic Response
Age effect: Elderly rats have weaker metabolic response to Nefiracetam, with only a 10% increase in brain glucose uptake (compared to 18% in the young group), which may be related to mitochondrial dysfunction.
Gender differences: Female mice are more sensitive to the antioxidant effects of Nefiracetam, with a 22% increase in brain GSH levels compared to males. Further exploration of hormone regulatory mechanisms is needed.
Metabolic synergistic effects of combination therapy
Combined use with anti diabetes drugs: Nefiracetam (50 mg/kg) and metformin (200 mg/kg) can synergistically reduce the brain insulin resistance index (HOMA-IR) of Alzheimer's disease model mice by 38%, which is superior to single drug treatment.
Synergistic with antioxidants: Combined with N-acetylcysteine (NAC), it can further reduce brain MDA levels by 45% and enhance neuroprotective effects.
Monitoring of long-term metabolic safety
Lipid metabolism risk: Long term high-dose Nefiracetam (≥ 400 mg/d) may slightly increase serum triglyceride (TG) levels (average+15%), and attention should be paid to cardiovascular metabolic side effects.
The impact on gut microbiota: Preliminary studies have shown that Nefiracetam can alter the composition of gut microbiota (such as increasing the abundance of Akkermansia), and its metabolites (such as short chain fatty acids) may indirectly affect brain energy metabolism, which requires further exploration.
Hot Tags: nefiracetam capsules, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale